PATHOPHYSIOLOGY, INVESTIGATIONS, AND TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA
OMAR ELSAKA *
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
MONEER AYMAN NOURELDEAN
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
MOHAMED ADEL GAMIL
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
MOSTAFA TAREK GHAZALI
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
ASHRAF HAMADA ABD AL-RAZIK
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
DALIA HISHAM
Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.
*Author to whom correspondence should be addressed.
Abstract
In otherwise healthy children or adults, immune thrombocytopenic purpura (ITP) has a low platelet count, usually less than 100,000, in the presence of common petechiae, bruises, or bleeding. It is explained that there is. ITP is most commonly found in children of all ages, not just adults. This activity describes the role of an inter-expert team in the evaluation and treatment of patients with immune thrombocytopenic purpura (ITP). The aim of this review article is to determine the etiology of immune thrombocytopenic purpura, formulate the patient's unique presentation with ITP, interpret general physical exam findings associated with ITP, and improve coordination of care among international team members. Outcomes will be discussed for patients with ITP.
Keywords: Varietal preference, Hematoma, Ovicides, idiopathic thrombocytopenic purpura, persistence, petechiae, new generation pesticides, platelets